March 27, 2024

Deciphex Announce Web Based Enhancements to Patholytix, Enabling Any Time, Anywhere Peer Review

With the release of Patholytix 4.0, Deciphex introduces a new workflow, enabling users to access the platform through the web. Patholytix’s web-workflow enhances collaboration within the pharmaceutical industry, between Contract Research Organizations (CROs), Pharma sponsors and independent Consultant Pathologists worldwide using best of breed technology to deliver high performance and ergonomic workflows. This innovation marks another significant milestone for accessibility and flexibility in non-clinical study participation, enabling seamless collaboration regardless of location or technological constraints.

The new workflow offers an intuitive web-based interface, empowering users with the ability to access and review studies from any device, anywhere in the world. In addition to our high performance pathology cockpit, web based workflows eliminate the delays introduced at the IT setup phase and allows effortless integration into existing workflows.

Facilitating easier study reviews across various scenarios, the Patholytix web workflow enables peer review by CRO pathologists at different locations, pathologists at Sponsor sites, as well as independent consultant pathologists. By providing instantaneous access to studies post-primary review, Patholytix eliminates the logistical challenges of shipping slides or travelling to test sites for peer reviewers, thereby expediting study completion and accelerating progress towards clinical trials.

“Until now, the need for IT installation has delayed some of our partners from collaborating effectively with one another digitally on drug safety studies” said Shane Ryan, General Manager of Preclinical Pathology at Deciphex. “The addition of a web-based workflow solves another challenge delaying drug development cycles. The web workflow now puts the power of Patholytix into the hands of study collaborators no matter where they are located or the device they’re using. This gives pharma companies and CROs more freedom when selecting study collaborators. This freedom will result in better scheduling, faster study completion, and thus quicker decisions on new drugs.”

For more information on The Patholytix web-workflow and the upgrades in Patholytix 4.0, please contact info@deciphex.com, or VP of Business Development Colin Doolan at colin.doolan@deciphex.com.

About Deciphex:

Deciphex is a pioneering company at the forefront of the digital transformation of pathology. By networking with global pathologists and leveraging AI-driven solutions, Deciphex accelerates certainty in pathology reporting, ultimately enhancing patient care and advancing drug development. For more information, visit https://www.deciphex.com.

For media inquiries, please contact:

Charli-Ann Lynch
Product Marketing Specialist
charli-ann.lynch@deciphex.com
+353 872401459

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No items found.
return to news

Contact Details

Invent Buidling at DCU

Ireland

Deciphex
DCU Alpha Building, Innovation Campus,
11 Old Finglas Rd, Glasnevin, Co. Dublin
D11 KXN4

Call: +353 1 582 7193

Email: Info@deciphex.com

Twitter: @deciphex

USA Headquarters Building

USA

Deciphex Inc.
1012 95th Street, Naperville,
Chicago, Illinois
60564

Call: +1 708 573 0674

Email: info@deciphex.com

USA Headquarters Building

UK

Diagnexia
Exeter Science Park Centre,
6 Babbage Way, Exeter
EX5 2FN

Call: +44 1 29730 2245

Email: Info@deciphex.com

Email Us

The details you submit will be used so that we can contact you in relation to your query either by email or your preferred method of contact. Read our privacy policy here.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form
Copyright Deciphex 2021
By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.